FGEN: יחס מחיר למכירות FibroGen Inc

A liquidity crisis and the threat of bankruptcy due to failed trials place FibroGen, Inc. (FGEN) in a precarious position. The price/sales multiple illustrates this instability, where 4.70 captures the current state of the parameter. The firm's survival relies on royalties from Asia amid collapsed pricing power, while its primary earnings are based on roxadustat sales through strategic partners.

The P/S metric is critical for stress-testing assets and identifying overvalued companies, as it compares market capitalization to annual sales volume to demonstrate how much investors are willing to pay per unit of revenue. The current price/sales multiple for FibroGen, Inc. (FGEN) is 4.70. This chart confirms the resilience of FibroGen, Inc., whose biotechnological developments are shielded from macroeconomic shocks due to stable demand for innovative medicine.